TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in self-reports of alcohol with the time-line follow-back (TLFB) in the last 90 days
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the Short Alcohol Dependence Data Questionnaire (SADD)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the Inventory of consequences associated with alcohol use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the Severity of dependence scale (SDS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Wisconsin Smoking Withdrawal Scale - anger
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Wisconsin Smoking Withdrawal Scale - anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Wisconsin Smoking Withdrawal Scale - sad
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in postoperative pain intensity level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Widening of retropalatal area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of daytime sleepiness
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Snoring intensity and frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility assessed as session attendance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability as indicated by participant satisfaction ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of Treatment Emergent adverse events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Time of insertion of supra glottic device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Behavioural and Psychological Symptoms of Dementia (BPSD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of Depression in dementia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Verbal and non-verbal aspects of communication in dementia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to complete re-epithelialization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean total score change as per scale r-TNSS (AM/PM)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area of the Meibomian Glands (MGs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Width-to-Width (WTW) distance of the cornea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients presenting with sudden cardiac death, sustained ventricular arrhythmia, or defibrillator therapy
Endpoint domain: Mortality/survival
Primary endpoint: estimated blood loss during cesarean delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Vorasidenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach Maximum Observed Plasma Concentration (Tmax) for Vorasidenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to the Last Quantifiable Concentration (AUC0-t) for Vorasidenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Schneiderian membrane thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perforation of the Schneiderian membrane
Endpoint domain: Adverse events/effects
Primary endpoint: Immediate urinary continence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of proptosis responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of IHC results with patient outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Child Mental Health Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Externalizing Behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: motor coordination competence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropathic symptoms score (NSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Multiple Sclerosis Quality of Life Scale (MSQOL)-54
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: PERMA Measuring Tool
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in I-PSS Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days on total parenteral nutrition
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: best renal response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Residual cancer burden class (RCB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Functional and phenotypical characterization of lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prevalence of functional heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Model for End-Stage Liver Disease (MELD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee and Osteoarthritis Outcome Score for Children (KOOS-Child) 'Sport / Recreation' subscale change from baseline
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: nalbuphine consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Exercise capacity in watt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rating of perceived exertion Borg RPE scale 6-20
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ulcer size at week 4 (percent area reduction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of the BariTon™
Endpoint domain: Adverse events/effects
Primary endpoint: Sound detection performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speech discrimination performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall DQ on the BLR scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Clinical staging of thyroid cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of participants with IGA-CPG-S score 0 or 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with ≥ 4-point improvement in WI-NRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: effectiveness of first-line treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Competence in SGM Care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with normal lung impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of participants with normal total pulmonary resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of patients with an identified genetic abnormality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from baseline in Hamilton Depression Rating Scale (HAMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Young Mania Rating Scale (YMRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hiatal Hernia Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in SRS-22r score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Motor subtypes evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep quality evaluation
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Neonatal N. lactamica colonisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Intention to use tobacco
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time taken to recover from abdominal surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain in the postanesthesia care unit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: agitation in the postanesthesia care unit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of coronary non-target lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post-Concussion Symptom Scale (PCSS) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Plasma concentration-time profile over 24h (AUCs) of avenanthramides and avenacosides and their metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: early response to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QDASH score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: percentage of aplastic anemia among causes of pancytopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Hamilton Depression Scale (HAMD-17)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pittsburgh Sleep Quality Scale (PSQI)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Changes in Beck Suicidal Scale Inventory (BSI)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in selective attention through eye-tracking task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in cerebral blood flow of left DLPFC through Near Infrared Spectroscopy (fNIRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Impact of Female Chronic Pelvic Pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Signal to Noise Ratio of the recorded brain activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of Meropenem prescriptions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Efficacy of NV-5138
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain reduction in the target shoulder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aneurysm diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MARS-i
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: EEG frequency bands
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Penumbra volume change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Symmetry index between the operated limb and the healthy contralateral limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical neurological outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline Advance Care Planning Engagement Survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mechanical power changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastrointestinal Pressure (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in DesStO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in tM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived PDM acceptance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived PDM usability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: prostaglandinE2 (PGE2) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TNF alpha ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: TGF beta ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect on glucose homeostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Medication adherence to secondary prevention drugs for stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen saturation in blood (SpO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Very good partial response or better (VGPR or better) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion Rate of an HMR Intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Tolerability of JR-441
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of JR-441
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of Complete Remission (DoCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment Satisfaction Questionnaire for Medication Version 9 (TSQM-9) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-expression and Emotion Regulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: blood-oxygen-level-dependent (BOLD) signal changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional connectivity (FC) changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: behavioral inhibition system (BIS)/behavioral activation system (BAS) scale score changes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Participant degree of acceptance of intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participants perception of intervention applicability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Facilitators perception of difficulty of implementing the intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Host response in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Host response in respiratory tract
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Circulating HPV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Bimanual Learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Symmetric performance and tangential velocities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Resting Motor Threshold (rMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Active Motor Threshold (aMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of reactogenicity events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of extubation failure
Endpoint domain: Adverse events/effects
Primary endpoint: Lung cytokine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Wong Baker Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotional Indicators Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Post-surgical complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Degree of anxiety/reassurance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Expectations of patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain severity evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Vitreous Hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Mean of total eye score changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean of thyroid eye disease Quality of life score changes
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Validity evidence for the theoretical test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central endothelial cell loss (ECL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in gut microbiota diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant acceptance of randomization arm / intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participant use of digital health and/or community health worker interventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Frequency of participation in the online therapeutic education program
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: heart rate variability at night work
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: heart rate variability at day work
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Expression of LTBP4 in renal fibrotic tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Expression of biomarkers in renal fibrotic tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of category II fetal heart rate tracing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients with SBP decrease within target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nutritional risk screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient-generated subjective nutrition assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Anxiety Score from immediately before to immediately after cystoscopy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Door-to-treatment-time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Depression Severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Correct ultrasound view acquisition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance to the treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: AHI index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRD clearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol use reductions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with treatment effectiveness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acute PVI during index procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long term efficacy
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of eligible patients who agree to participate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Completion rates of survey measures
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability of the online intervention expressed by patients
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postoperative pain measured by FLACC scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention/Engagement - completion
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Retention/Engagement - activity
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Usability of the app
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Accuracy and precision of pleural and ascites drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Laryngeal Air Column Width Difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Antitumor efficacy of immunotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of Supraventricular tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Ventricular tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Conduction disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Burden of Gram Negative organisms infections
Endpoint domain: Adverse events/effects